HC Wainwright & Co. Maintains Buy on Nurix Therapeutics, Raises Price Target to $36
Benzinga Newsdesk 2 weeks ago
Analyst RatingsNewsPrice Target
HC Wainwright & Co. analyst Robert Burns maintains Nurix Therapeutics (NASDAQ:NRIX) with a Buy and raises the price target from $34 to $36.
HC Wainwright & Co. analyst Robert Burns maintains Nurix Therapeutics (NASDAQ:NRIX) with a Buy and raises the price target from $34 to $36.